Riskpilot← Back to searchSign inGet full accessBORGEÅSEN APOTEK AS
ASActiveOrg 923833668Buervegen 14, 3711 SkienRetail sale of pharmaceutical products · NACE 4773Est. 20198 employees
Revenue 2023
NOK 16,3M
+8% vs 2022
EBITDA margin
1.9%
+302% vs 2022
Equity ratio
9.6%
Financial strength
Net profit 2023
NOK 102K
+142% vs 2022
| Revenue | NOK 16,3M | +8% |
| EBITDA | NOK 314K | +302% |
| Net profit | NOK 102K | +142% |
| Total assets | NOK 4,4M | +22% |
| Equity | NOK 418K | +599% |
| Employees | 8 | — |
Legal name
BORGEÅSEN APOTEK AS
Org number
923833668
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
16. november 2019
Share capital
NOK 801 000
Employees
8 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Eie og drive apotek og alt hva hermed står i forbindelse.
Address
Buervegen 14, 3711 Skien
Phone
+4794796534
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 0 | 8 919 | 13 532 | 15 045 | 16 260 |
| Staff expenses | −0 | −2 077 | −3 173 | −3 477 | −3 569 |
| EBITDA | −69 | −69 | −310 | −155 | 314 |
| Depreciation & amort. | −1 | −108 | −130 | −130 | −131 |
| EBIT | −70 | −177 | −440 | −285 | 183 |
| Net financials | 0 | −74 | −45 | −28 | −51 |
| Profit before tax | −70 | −251 | −485 | −314 | 131 |
| Tax | −0 | −73 | −107 | −69 | 29 |
| Net profit | −70 | −178 | −379 | −245 | 102 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 740 | 3 513 | 2 882 | 3 580 | 4 380 |
| Equity | 717 | 539 | 161 | −84 | 418 |
| Long-term debt | 0 | 1 250 | 612 | 419 | 226 |
| Short-term debt | 23 | 1 723 | 2 109 | 3 245 | 3 736 |
| Total debt | 23 | 2 973 | 2 721 | 3 664 | 3 962 |
EBITDA margin
1.9%
This company
15.8%
Market median
-88% vs market
20192023
Equity ratio
9.6%
This company
38.2%
Market median
-75% vs market
20192023
Return on equity
24.4%
This company
18.4%
Market median
+33% vs market
20192023
Net profit margin
0.6%
This company
8.1%
Market median
-93% vs market
20192023
Asset turnover
3.71×
This company
1.12×
Market median
+231% vs market
20192023
Debt / equity
9.47×
This company
0.62×
Market median
-1427% vs market
20192023
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AB Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Chairman | 2022 | |
| Former (2) | ||
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2022 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Apoinvest Holding As
BORGEÅSEN APOTEK AS Board members of BORGEÅSEN APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Brekke | Chief Executive Officer | 0 companies |
| Vegard Hoff | Board of Directors | 0 companies |
| Michael Roland Ecker | Chairman | 0 companies |
| Bjarne Brudeli | Board of Directors | 0 companies |
| Einar Mathias Teigen Rasch-Halvorsen | Chairman | 0 companies |
| Gulzeb Aziz | Board of Directors | 0 companies |